Brand name: Enhertu
Chemical name: Fam-trastuzumab-deruxtecan-nxki
Class: Antibody-drug conjugate targeted therapy. Enhertu is made up of three parts:
- fam-trastuzumab: an anti-HER2 medicine that has the same basic structure as Herceptin (chemical name: trastuzumab)
- a topoisomerase I inhibitor chemotherapy called DXd: topoisomerase-I inhibitors work by interfering with the cancer cells’ ability to replicate; this type of chemotherapy is not typically used to treat HER2-positive breast cancers, so researchers believe it is less likely that the cancers will develop resistance to it
- a compound that links the fam-trastuzumab molecule to the topoisomerase I inhibitor chemotherapy molecule
The combination of the topoisomerase I inhibitor and the linking compound is called deruxtecan. The linking compound attaches (conjugates) the fam-trastuzumab to the topoisomerase I inhibitor chemotherapy.
Kadcyla is another antibody-drug conjugate targeted therapy used to treat breast cancer.
Uses: Enhertu is used to treat unresectable (not able to be removed with surgery) and metastatic HER2-positive breast cancer that has been treated with two or more anti-HER2 therapies.
How it’s given: Enhertu is given intravenously, which means the medicine is delivered directly into your bloodstream through an IV or port.
Additional information: The topoisomerase I inhibitor chemotherapy part of Enhertu, like other chemotherapy medicines, interferes with cells’ ability to replicate. The topoisomerase I inhibitor isn’t a targeted medicine, which means it can affect healthy cells as well as cancer cells. Enhertu was designed to deliver the topoisomerase I inhibitor to cancer cells in a targeted way by attaching the topoisomerase I inhibitor to the fam-trastuzumab. The fam-trastuzumab then carries the topoisomerase I inhibitor to the HER2-positive cancer cells. This way, the topoisomerase I inhibitor is less toxic to healthy cells and more effective in treating cancer cells.
- severe lung inflammation
- heart problems
- hair loss
- decreased appetite
- low white blood cell counts
Read more about Enhertu.
- Enhertu prescribing information, 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf (PDF).
Can we help guide you?
Create a profile for better recommendations
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
Eating When You Have Nausea and Vomiting
Almost all breast cancer treatments have varying degrees of risk for nausea and vomiting. Some...
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....